GVR Report cover Cell-based Assays Market By Product & Services (Microplate, Reagents, Assay Kits, Cell Lines, Instruments & Services), By Application, By End-user, By Region, And Segment Forecasts, 2022 To 2030Report

Cell-based Assays Market By Product & Services (Microplate, Reagents, Assay Kits, Cell Lines, Instruments & Services), By Application, By End-user, By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453198
  • Number of Pages: 0
  • Format: Electronic (PDF)

Cell-based assays could be used in both drug-discovery screening and biomedical research applications to efficiently quantify biochemical mechanisms, cytotoxicity, off-target interactions, and biological activity. The potential advantage of these assays includes the generation of complex and biologically relevant data. Several technologies are being used in the drug development process, such as genome editing tools like CRISPR/Cas9 which drives the adoption of cell-based assays in R&D. These assays form an integral part of life science research, providing a proper understanding of several cellular phenomena in disease and health. Moreover, in a regulatory setting, these assays are also utilized for cytotoxicity testing, determining the mechanism of action, and immunogenicity studies.

Furthermore, advancements in therapeutics platforms such as gene and cell therapies, offer a promising approach to precision medicine by introducing genes to targeted tissues or cells. Novartis AG is working towards the development of cell-based assays to offer high-quality and safe therapeutics in gene therapy. Similarly, in March 2022, Promega Corporation entered into a strategic collaboration with FUJIFILM Cellular Dynamics, Inc., that aims to advance assay development for drug discovery. Continuous advancements in this field by the companies would drive the growth of the market.

Some of the applications have been trifurcated as:

  • Personalized Medicine

  • Gene Therapy

  • Bioprocessing

Cell-based assays are a crucial tool to characterize the functionality of biosimilars and biologics. Cultured cells provide a proper representation of the physiological conditions in which the drug function. The key application for the specific cell-based assays is mode of action (MOA) research during cytotoxicity, comparability assessment, drug development assessment, and biosimilar development. Another key factor driving the growth of the market is the significant adoption of technologies for high throughput screening methods such as drug screening, toxicity studies, invitro studies, and others. These factors are further fueling the growth of the market.

The pharmaceutical industry needs to commercialize drugs efficiently to drive innovation in the market. The industry is adopting this approach to reverse the increasing trend of costly late-stage drug failures. The rapid assay-based techniques are in huge demand to predict a higher degree of accuracy in which investigation of the new drug would be successful till commercialization. These factors are driving the growth of the market.

Cell-based Assay Market Segmentation

Segments

Details

Product

Consumable, Assay Kits, Cell Lines, Service, Instrument, Software

End-user

Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Government Research Institutes, Others

Application

Drug Discovery, ADME Studies, Basic Research, Predictive Toxicology, Others

Regional

North America, Europe, Asia-Pacific, Latin America, MEA

 

Major players operating in the cell-based assay market includes Novartis AG, BD, Beckman Coulter, Inc., Danaher, General Electric, Merck KGaA, Thermo Fisher Scientific, Inc., Lonza, Cell Signaling Technology, Inc., Perkinelmer, Inc., Bio-Rad Laboratories, Inc., and Promega Corporation.

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.